For example, combining cytokine-targeted therapies(e.g., IL-1 inhibitors) with non-specific anti-inflammatory agents (e.g.,statins) could synergistically inhibit inflammatory cascades throughmulti-pathway mechanisms, thereby reducing AF recurrence risk. This evidence concerns the gene IL1B and atrial fibrillation.